Nevertheless, IL12/23p40–targeted therapy in patients with established multiple sclerosis was ineffective (121), whereas the impact of IL-23p19 subunit inhibition in this patient population has yet to be determined. The gene discussed is IL23A; the disease is multiple sclerosis.